Last updated: July 23, 2026
VALEANT PHARMACEUTICALS v. PAR STERILE PRODUCTS (2:17-cv-06449): Litigation Summary, Claims at Issue, and Settlement/Exposure Analysis
Executive summary: Valeant Pharmaceuticals International Inc. v. PAR Sterile Products, LLC (E.D. Pennsylvania, case no. 2:17-cv-06449) is a federal patent-infringement dispute filed in 2017 concerning Valeant’s rights tied to sterile pharmaceutical products. The record available here does not include the complaint caption details, asserted patents, claim construction, infringement allegations, case disposition, or any settlement terms. With no access to the underlying docket filings, no complete and accurate litigation summary, claim-by-claim analysis, or exclusivity-to-launch risk mapping can be produced from the case number alone.
What patents were asserted in VALEANT PHARMACEUTICALS INTERNATIONAL INC. v. PAR STERILE PRODUCTS, LLC (2:17-cv-06449)?
No specific asserted-patent identifiers, publication numbers, or patent numbers can be stated from the case number alone.
Which patent(s) did Valeant allege PAR Sterile infringed?
Not available in the provided data.
Were method-of-use, formulation, or manufacturing process claims at issue?
Not available in the provided data.
What procedural posture did 2:17-cv-06449 reach in the district court?
A complete posture requires docket milestones (motions to dismiss, claim construction, summary judgment, trial dates, and final judgment).
What dates were key events in the case?
Not available in the provided data.
Were there claim construction rulings or substantive invalidity findings?
Not available in the provided data.
How did the court address infringement, anticipation/obviousness, and claim scope in 2:17-cv-06449?
A legal analysis requires claim construction orders and substantive opinions. Those are not present in the provided information.
What claim terms were construed?
Not available in the provided data.
What were PAR’s principal defenses (non-infringement, invalidity, inequitable conduct)?
Not available in the provided data.
Did PAR file an ANDA, 505(b)(2), or 351(k) pathway notice that triggered Paragraph IV or similar litigation?
The linkage between the court case and any FDA regulatory filing requires the Orange Book/notice details and docket exhibits.
Was there a Paragraph IV notice, and for which listed patents?
Not available in the provided data.
What FDA action date and approval/launch timeline did the litigation affect?
Not available in the provided data.
What is the settlement status of VALEANT PHARMACEUTICALS INTERNATIONAL INC. v. PAR STERILE PRODUCTS, LLC (2:17-cv-06449)?
Settlement status depends on docket disposition (stipulated dismissal, consent judgment, licensing agreement, or ongoing injunctive relief).
Was the case dismissed, settled, or resolved by judgment?
Not available in the provided data.
Did the parties agree to covenants not to sue, launch restrictions, or design-around terms?
Not available in the provided data.
What injunction or remedies did Valeant seek in 2:17-cv-06449, and what did it obtain?
Remedies analysis requires the requested relief in the complaint and the final order.
Was injunctive relief granted or denied?
Not available in the provided data.
Was damages relief pursued (reasonable royalty, lost profits) and did the court address it?
Not available in the provided data.
How does this case compare with other Valeant vs. sterile compounding or generic manufacturer disputes?
A comparative analysis requires a set of other cases’ asserted patents, outcomes, and settlements, which is not included here.
What similarities exist in claim types and litigation strategy?
Not available in the provided data.
What differences exist in the parties’ trial postures and outcomes?
Not available in the provided data.
What generic entry or biosimilar entry risks does 2:17-cv-06449 create for PAR or other manufacturers?
Entry-risk modeling requires: (i) the asserted patents and scope, (ii) the court’s rulings, (iii) whether the resolution was with prejudice or subject to appeal, and (iv) any settlement that caps entry.
Could other manufacturers rely on the same design-around or invalidity theories?
Not available in the provided data.
Does the case signal enforceability weakness or strengthen Valeant’s patent estate?
Not available in the provided data.
Key Takeaways
- The case number 2:17-cv-06449 identifies a federal infringement dispute, but the provided information does not include docket filings or substantive orders.
- Without complaint assertions, claim construction, merits rulings, and disposition data, a factual litigation summary and enforceability/exposure analysis cannot be completed accurately.
FAQs
- What court handled VALEANT PHARMACEUTICALS INTERNATIONAL INC. v. PAR STERILE PRODUCTS, LLC (2:17-cv-06449)?
- What procedural motions are typically decisive in patent cases like 2:17-cv-06449 (dismissal, claim construction, summary judgment)?
- How do Paragraph IV notices usually connect to Valeant patent suits against generic sterile products?
- What remedies are commonly sought by branded patent holders in sterile drug infringement actions?
- How should investors or licensing teams evaluate settlement value in disputes like 2:17-cv-06449?
References
- United States District Court, Eastern District of Pennsylvania. Valeant Pharmaceuticals International Inc. v. PAR Sterile Products, LLC, No. 2:17-cv-06449.
